Cardiothoracic & vascular anesthesia
A randomised controlled trial of dexmedetomidine for delirium in adults undergoing heart valve surgery
Primary resultResult — go to the resultAdjusted relative risk 0.86 95% CI 0.56–1.33Authors' conclusion
Intra-operative dexmedetomidine infusion did not reduce the incidence of delirium after cardiac valve surgery but might impair renal function.
Study context
- Population
- Adults undergoing heart valve surgery
- Participants
- 652 adults
- Comparison
- Intra-operative dexmedetomidine infusion vs saline
- Dexmedetomidinen = 326
- Placebon = 326reference
- Primary endpoint
- Delirium
- Follow-up
- First seven postoperative days
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Adjusted relative risk
0.86
95% CI 0.56–1.33
P = 0.51
Events by treatment group
Dexmedetomidine
47
events
Placebo
51
events
Dexmedetomidine vs Placebo
adjusted RR 0.86 (95% CI 0.56–1.33); P = 0.51
- Delirium overall
- 98/652 (15%)
Safety
| Outcome | P value |
|---|---|
| Postoperative renal impairment (KDIGO stages 1, 2 and 3) | P = 0.040 |
- Postoperative renal impairment (KDIGO stages 1, 2 and 3) — Dexmedetomidine: stages 1, 2, 3
- 46, 9 and 2
- Postoperative renal impairment (KDIGO stages 1, 2 and 3) — Placebo: stages 1, 2, 3
- 25, 7 and 4
Original publication
A randomised controlled trial of dexmedetomidine for delirium in adults undergoing heart valve surgery. Anaesthesia. Published 16 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →